Header Logo

Connection

Lee Fairlie to Male

Back to Details
This is a "connection" page, showing publications Lee Fairlie has written about Male.
Lee Fairlie
Connection Strength
0,941
Male
  1. High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa. Medicine (Baltimore). 2018 Jul; 97(29):e10901.
    View in: PubMed
    Score: 0,067
  2. CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. AIDS. 2015 Oct 23; 29(16):2109-19.
    View in: PubMed
    Score: 0,056
  3. Providing comprehensive health services for young key populations: needs, barriers and gaps. J Int AIDS Soc. 2015; 18(2 Suppl 1):19833.
    View in: PubMed
    Score: 0,053
  4. Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa. Int J Tuberc Lung Dis. 2014 Jun; 18(6):676-81.
    View in: PubMed
    Score: 0,050
  5. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis. 2011 Jan 26; 11:28.
    View in: PubMed
    Score: 0,040
  6. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 Feb; 9(2):100-111.
    View in: PubMed
    Score: 0,026
  7. Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial. Hum Vaccin Immunother. 2025 Dec; 21(1):2450120.
    View in: PubMed
    Score: 0,026
  8. Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis. N Engl J Med. 2024 Dec 19; 391(24):2315-2326.
    View in: PubMed
    Score: 0,026
  9. A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis. NEJM Evid. 2025 Jan; 4(1):EVIDoa2400190.
    View in: PubMed
    Score: 0,026
  10. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2425147.
    View in: PubMed
    Score: 0,026
  11. South African Parents' and Grandparents' Perspectives on the Acceptability of Implant Delivery of Treatment to Young Children with HIV. AIDS Behav. 2025 Jan; 29(1):13-21.
    View in: PubMed
    Score: 0,026
  12. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study. HIV Med. 2024 Jul; 25(7):826-839.
    View in: PubMed
    Score: 0,025
  13. Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trial. AIDS. 2024 07 15; 38(9):1304-1313.
    View in: PubMed
    Score: 0,025
  14. Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents. Clin Pharmacokinet. 2023 10; 62(10):1445-1459.
    View in: PubMed
    Score: 0,024
  15. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet HIV. 2023 06; 10(6):e363-e374.
    View in: PubMed
    Score: 0,023
  16. Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial. PLoS One. 2021; 16(8):e0255250.
    View in: PubMed
    Score: 0,021
  17. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
    View in: PubMed
    Score: 0,021
  18. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 01 09; 397(10269):99-111.
    View in: PubMed
    Score: 0,020
  19. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676.
    View in: PubMed
    Score: 0,020
  20. Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. PLoS One. 2020; 15(5):e0233693.
    View in: PubMed
    Score: 0,019
  21. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2020 07; 20(7):851-863.
    View in: PubMed
    Score: 0,019
  22. Earlier Antiretroviral Therapy Initiation and Decreasing Mortality Among HIV-infected Infants Initiating Antiretroviral Therapy Within 3 Months of Age in South Africa, 2006-2017. Pediatr Infect Dis J. 2020 02; 39(2):127-133.
    View in: PubMed
    Score: 0,019
  23. The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial. PLoS One. 2020; 15(1):e0228003.
    View in: PubMed
    Score: 0,019
  24. Association between caregiver depression symptoms and child executive functioning. Results from an observational study carried out in four sub-Saharan countries. AIDS Care. 2020 04; 32(4):486-494.
    View in: PubMed
    Score: 0,018
  25. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 08 29; 381(9):803-815.
    View in: PubMed
    Score: 0,018
  26. What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies. Pediatr Infect Dis J. 2019 04; 38(4):400-405.
    View in: PubMed
    Score: 0,018
  27. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials. 2018 Dec 20; 19(1):693.
    View in: PubMed
    Score: 0,017
  28. Mortality and losses to follow-up among adolescents living with HIV in the IeDEA global cohort collaboration. J Int AIDS Soc. 2018 12; 21(12):e25215.
    View in: PubMed
    Score: 0,017
  29. Lamivudine monotherapy as a holding regimen for HIV-positive children. PLoS One. 2018; 13(10):e0205455.
    View in: PubMed
    Score: 0,017
  30. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med. 2018 07; 15(7):e1002591.
    View in: PubMed
    Score: 0,017
  31. Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial. AIDS. 2018 01 14; 32(2):189-204.
    View in: PubMed
    Score: 0,016
  32. Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial. PLoS One. 2017; 12(6):e0178075.
    View in: PubMed
    Score: 0,016
  33. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Clin Infect Dis. 2016 10 15; 63(8):1113-1121.
    View in: PubMed
    Score: 0,015
  34. Outcomes of Infants Starting Antiretroviral Therapy in Southern Africa, 2004-2012. J Acquir Immune Defic Syndr. 2015 Aug 15; 69(5):593-601.
    View in: PubMed
    Score: 0,014
  35. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children. Pediatr Pulmonol. 2016 Feb; 51(2):157-64.
    View in: PubMed
    Score: 0,014
  36. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa. Pediatr Infect Dis J. 2015 Feb; 34(2):175-9.
    View in: PubMed
    Score: 0,013
  37. Evaluation of parent-child pairs on antiretroviral therapy in separate adult and pediatric clinics. J Int Assoc Provid AIDS Care. 2014 Nov-Dec; 13(6):555-9.
    View in: PubMed
    Score: 0,012
  38. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. AIDS. 2013 Mar 13; 27(5):781-5.
    View in: PubMed
    Score: 0,012
  39. Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa. Glob Health Action. 2013 Jan 24; 6:19248.
    View in: PubMed
    Score: 0,011
  40. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One. 2011 Feb 23; 6(2):e17273.
    View in: PubMed
    Score: 0,010
  41. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther. 2011; 16(3):417-21.
    View in: PubMed
    Score: 0,010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.